SCHEMBL23218182

SCHEMBL23218182

CCOC(=O)Cc1ccccc1OCc1coc2c(COc3ccc(F)cc3)cc(Br)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.38
TSHR P16473 1/20 0.38
TBXAS1 P24557 1/20 0.38
KMT2A Q03164 5/20 0.37
MEN1 O00255 4/20 0.37
POLB P06746 3/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MMP1 P03956 2/20 0.36
PPARD Q03181 2/20 0.36
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PRMT5 O14744 1/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
CFD P00746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852673 1.00 MAOB (0.38) MAOBTSHRTBXAS1KMT2AMEN1
SCHEMBL23219051 0.94 TBXAS1 (0.39) TSHRTBXAS1KMT2AMEN1POLB
SCHEMBL29852526 0.94 TBXAS1 (0.39) TSHRTBXAS1KMT2AMEN1POLB
SCHEMBL29853078 0.88 TBXAS1 (0.40) TBXAS1KMT2AMEN1POLBNPSR1
SCHEMBL23218822 0.88 TBXAS1 (0.40) TBXAS1KMT2AMEN1POLBNPSR1
SCHEMBL23218255 0.87 TBXAS1 (0.41) TBXAS1KMT2AMEN1POLBNPSR1
SCHEMBL29592551 0.87 TBXAS1 (0.41) TBXAS1KMT2AMEN1POLBNPSR1
SCHEMBL29852978 0.87 TBXAS1 (0.41) TBXAS1KMT2AMEN1POLBNPSR1
SCHEMBL28736329 0.86 TBXAS1 (0.39) TBXAS1KMT2AMEN1POLBHPGD
SCHEMBL23218048 0.85 TBXAS1 (0.39) TBXAS1NPSR1ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAOB 1035/4885TSHR 1199/4885TBXAS1 963/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOB 453/4885TSHR 3148/4885TBXAS1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.